End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.92 EUR | -1.08% | +9.52% | -68.28% |
15/05 | Acticor: 'new perspectives' in stroke treatment | CF |
15/05 | Acticor Biotech Announces Presentation of the Main Results of the Phase 2/3 Actisave Study in the Treatment of Stroke at ESOC 2024 | CI |
Official Publications
- Stock Market
- Equities
- ALACT Stock
- News Acticor Biotech SAS
- Official Publications